Zhang et al. [470] used CRISPR/Cas9 to construct lymphocyte activation gene-3 (LAG-3)-deficient CAR-T cells and discovered that these cells had potent anti-tumor activity in both in vitro and in vivo settings. The gene discussed is LAG3; the disease is neoplasm.